-
2022-08-09
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces its top-line Phase 3 ENHANCE-2 ("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary d
-
2022-07-26
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
Nuance Pharma announces the completion of dosing for all HNVs in the Phase I clinical study of its novel Ketorolac for IV infusion (NTM-001), a non-opioid analgesic drug co-developed with N
-
2022-07-13
Nuance Pharma advances Rare Disease R&D with CORD
July 11th, 2022, Mr. Mark Lotter, founder and CEO of Nuance Pharma, visited Chinese Organization for Rare Disorders (CORD) and met with Mr. Huang Rufang, founder and president of CORD.
-
2022-06-27
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs
-
2022-06-17
Strategic Cooperation Agreement with SHAPHAR
June 16th, 2022, Nuance Pharma signed Strategic Cooperation Agreement with Shanghai Pharmaceutical Co., Ltd. (Shanghai Pharma).
-
2022-06-09
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Verona Pharma plc (Nasdaq: VRNA) announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-1 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”).
-
2022-03-04
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio™, its nasal spray for protection against airborne viruses and allergens, with Nuance Phar
-
2022-01-06
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
Nuance Pharma announced an agreement with Sino Health Pharmaceutical Limited to fully acquire its 100-percent equity shares and its fully-owned subsidiaries Ying Lian Zhuhai and Ying Lian Germany.
Contact PR
![](/Public/Cn/images/f1_img_03.jpg)